| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10156580 | International Journal of Radiation Oncology*Biology*Physics | 2018 | 9 Pages |
Abstract
CCRT with daily low-dose cisplatin for locally advanced stage III NSCLC resulted in promising overall survival (3-year survival rate of 52% and 5-year survival rate of 40%) with low toxicity. Lymph node GTV, tumor GTV, and sex were predictors of overall survival, treatment toxicity, and distant metastasis.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Edith M.T. MD, Apollonia L.J. PhD, Meike W. MD, Rob M. van Os, Jan Wiersma, Mia G.J. MD, Merel Willemijn MD, Caro C.E. Koning, Judit A. MD, Hein J. PhD, Jouke T. Annema, Coen R.N. Rasch,